People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Healthtech, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Acutus Medical, Inc. | — | Healthtech | Series D+ | $296.3M | $69.0M | 2016 |
| Ikena Oncology, Inc. | — | Biotechnology | Series C | $117.6M | $449.1M | 2023 |
| Prelude Therapeutics Inc | — | Biotechnology | Series C | $115.0M | $1.9B | 2016 |
| Adela, Inc. | — | Biotechnology | Series C | $108.5M | $156.3M | 2021 |
| Tricida, Inc. | — | Pharmaceuticals | Series C | $103.1M | $2.0B | 2015 |
| Enobia Pharma Corp | — | Biotechnology | Series C | $100.0M | $819.2M | 2009 |
David Bonita at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Bonita on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew ElBardissi | 2 | 7 |
| Jean-Francois Formela | 1 | 17 |
| David Hirsch | 1 | 16 |
| Paul Brown | 1 | 12 |
| Robert Weisskoff | 1 | 12 |
| Kevin Johnson | 1 | 12 |
| Jonathan Silverstein | 1 | 10 |
| Steven Hochberg | 1 | 9 |
| Scott Huennekens | 1 | 7 |
| Klaus Veitinger | 1 | 6 |
| David Scheer | 1 | 6 |
| Paul Friedman | 1 | 5 |
| Iain Dukes | 1 | 5 |
| Eric L. Trachtenberg | 1 | 4 |
| Shahzad Malik | 1 | 4 |
| Owen Hughes | 1 | 4 |
| John Onopchenko | 1 | 4 |
| Otello Stampacchia | 1 | 4 |
| Aditya Puri | 1 | 4 |
| Thomas Schuetz | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.